Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Durham, North Carolina

Phase 1 colorectal cancer trials in Durham, NC

21 Phase 1 colorectal cancer studies are recruiting participants at sites in Durham as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Durham at a glance

  • 21 studies are recruiting at a site in Durham.
  • By phase: Phase 1 (11), Phase 1/2 (10).
  • By sponsor: industry (20), university, hospital or other (1).
  • Most recent update to one of these records: November 17, 2026.

Studies recruiting in Durham

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Duke University School of Medicine
    Registry record
    NCT05786924 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Duke Cancer Institute
    Registry record
    NCT06253871 · updated
  3. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Duke Cancer Center Durham
    Registry record
    NCT07488676 · updated
  4. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Duke University Medical Center
    Registry record
    NCT07213791 · updated
  5. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    Duke Health - Duke University Hospital
    Registry record
    NCT05856981 · updated
  6. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  7. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated
  8. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Duke University
    Registry record
    NCT05919264 · updated
  9. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Duke University
    Registry record
    NCT04585750 · updated
  10. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #12
    Registry record
    NCT05176483 · updated
  11. A Study of PHN-012 in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheon Therapeutics
    Study site
    PHN-012-001 Site
    Registry record
    NCT07127874 · updated
  12. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Phanes Therapeutics
    Study site
    Duke Cancer Center
    Registry record
    NCT05482893 · updated
  13. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Duke University Medical Center
    Registry record
    NCT06445062 · updated
  14. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    Duke University Medical Center - Duke Cancer Center
    Registry record
    NCT07217171 · updated
  15. Safety of HRX215 in Patients After Minor and Major Liver Resection

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    HepaRegeniX GmbH
    Study site
    Duke Cancer Institute
    Registry record
    NCT06638502 · updated
  16. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  17. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    Duke Cancer Center
    Registry record
    NCT07094113 · updated
  18. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Duke Cancer Institute /ID# 276267
    Registry record
    NCT05005403 · updated
  19. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Duke University Medical Center
    Registry record
    NCT03947385 · updated
  20. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Duke Cancer Center
    Registry record
    NCT06040541 · updated
  21. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Clasp Therapeutics, Inc.
    Study site
    Duke Cancer Institute
    Registry record
    NCT06778863 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Ask about studies near Durham

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call